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Background: We aimed to assess the safety and tolerability of different doses of canakinumab versus placebo in
patients with type 2 diabetes mellitus (T2DM).
Methods: Data were pooled from three studies in 1026 T2DM patients with different routes of administration,
treatment regimens and follow-up duration. Canakinumab groups were categorised as low (0.03 mg/kg i.v. once;
N = 20), intermediate (0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; N = 247), medium (1.5 mg/kg i.v. once,
50 mg s.c. monthly and 150 mg s.c. once; N = 268), and high doses (10 mg/kg i.v. once and 150 mg s.c. monthly;
N = 137) and compared with placebo (N = 354). Incidences of adverse events (AEs), serious AEs (SAEs),
discontinuations due to AEs, deaths, AEs of special interest related to interleukin-1β inhibition and T2DM disease,
and laboratory abnormalities related to haematology and biochemistry parameters were reported. Safety was also
analysed by age (<65, ≥65) and gender.
Results: Average exposure across all groups was ≈ 6 months (maximum ~17 months). No dose response in AEs
was observed but a trend towards more patients having at least one AE across canakinumab groups relative to
placebo (P = 0.0152) was observed. SAEs were few and the incidence rate for most canakinumab groups was lower
than that of placebo group except for the high-dose group (0.94% versus 0.58% per month in placebo). A total of
five patients discontinued treatment due to AEs across treatment groups. No death was reported in any of the
three studies. A small, non-significant increase in the incidence rate of infection AEs was observed on canakinumab
groups relative to placebo. Canakinumab was associated with mostly mild decreases in WBC, neutrophils and
platelet counts. Additionally, mild increases in SGPT, SGOT and bilirubin were reported. Overall, despite small
differences, no clinically relevant findings were observed with respect to laboratory values and vital signs.
Conclusions: This pooled analysis demonstrated that canakinumab was safe and well tolerated over a treatment
period up to 1.4 years at the four pooled doses evaluated, in agreement with safety findings reported in the
individual studies.
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Inflammation plays a major role in all the stages of ath-
erothrombosis, right from the initiation of endothelial
injury to the formation of plaque/thrombus in the cor-
onary arteries, which finally manifest into cardiovascular
diseases such as acute myocardial infarction and stroke
events [1,2]. Inflammation has also been recognised as an
important contributor to β-cell dysfunction and apoptosis
in type 2 diabetes mellitus (T2DM) patients [3-7]. Delay in
progression of inflammation can help in the prevention of
long-term cardiovascular risks.
Of the inflammatory molecules, interleukin-1 (IL-1)
plays a major role in atherothrombosis [8-10]. Evidence
supports the contribution of IL-1β isoform-mediated in-
flammation in atherogenesis and plaque progression,
worsening of β-cell function in the islets, and disease
progression [11-14].
One promising anti-inflammatory approach with po-
tential relevance for cardiovascular disease is inhibition
of the pro-inflammatory cytokine IL-1β. Canakinumab is
a human monoclonal IL-1β antibody of the IgG1/k iso-
type that blocks the interaction of this cytokine with its
receptors. This results in specific neutralisation of the
bioactivity of IL-1β, but does not prevent the binding of
the natural inhibitor IL-1Ra to the IL-1 receptor, nor the
binding to IL-1α [15,16]. Canakinumab targets IL-1β–
dependent inflammation, thereby potentially preserving/
improving pancreatic β-cell function and inhibiting pro-
gression to atherothrombosis in the coronary arteries of
T2DM patients who are at a high risk of developing
cardiovascular disease. Canakinumab significantly re-
duces systemic high-sensitivity C-reactive protein (hsCRP),
IL-6 and other inflammatory biomarker levels without
tolerability issues [15,17-19]. Canakinumab is also being
used to test the inhibitory effect on the inflammation in
atherothrombosis in the ongoing Canakinumab ANti-
inflammatory Thrombosis Outcome Study (CANTOS)
trial. This randomised study will determine whether the
long-term inhibition of IL-1β with canakinumab, as
compared with placebo, reduces the rate of recurrent
cardiovascular events among patients who are stable
post-myocardial infarction but are at an increased cardio-
vascular risk due to increased levels of hsCRP (≥2 mg/L)
despite usual care, including statin therapy [20].
In trials conducted to date, canakinumab has been asso-
ciated with minimal injection-site reactions, and a few side
effects due to IL-1β inhibition such as a small increase in
the risk of infections, reflecting the inhibition of innate
immunity achieved through canakinumab therapy. Infec-
tions were generally mild-to-moderate in severity, seldom
serious and resolved spontaneously or with standard
therapy [20].
On the basis of these considerations, it was of interest to
assess the safety and tolerability of canakinumab, as wellas the specific risk of adverse events (AEs) such as naso-
pharyngitis, urinary tract infections, thrombocytopenia
and neutropenia as reported in previous studies [21-26].
We pooled data from two phase II and one phase IIb stud-
ies [24-27] that used different canakinumab doses. These
studies were conducted in a relatively homogenous pool
of patients comprising of T2DM and/or impaired glucose
tolerance (IGT) patients. CANTOS is being conducted in
post-myocardial infarction patients in whom T2DM is a
common co-morbidity. Therefore, this integrated safety
analysis in patients with T2DM and IGT aimed to provide
additional support for the ongoing CANTOS trial with
regard to patient safety.
Methods
Populations
The pooled safety analyses are based on previously pub-
lished one phase IIb [24,25] and one phase II [26] studies,
and reported one phase II study [27], in 1026 randomised
patients. These studies were multicentre, randomised,
double-blind, placebo-controlled studies comparing cana-
kinumab with placebo in T2DM patients, on stable met-
formin monotherapy (except for one study [26] that
comprised five strata: T2DM + metformin, T2DM +
metformin/sulphonylurea, T2DM + metformin/sulpho-
nylurea/thiazolidinedione, T2DM + insulin ± metformin
and IGT patients). Both the phase II studies involved a
single canakinumab injection, but the length of the sub-
sequent follow-up differed [6 months follow-up in one,
and 1 month full follow-up (i.e. laboratory, vital signs
and all AEs) with an additional 3 months of follow-up
only for SAEs in the other]. The phase IIb study had a
monthly dosing schedule for a minimum of 4 months with
all patients continuing monthly canakinumab treatment
thereafter. This study had an interim efficacy analysis,
when all the enrolled patients had completed 4 months of
study drug, at which time the study was terminated due to
a lack of sufficient short-term glucose lowering effect in
T2DM patients.
Assessments
Treatment-emergent AEs, serious AEs (SAEs), discontinu-
ations due to AEs and deaths were assessed. Treatment-
emergent AEs and SAEs were recorded and assessed by
the investigator for their severity and possible relationship
with the study medication. Biochemistry, haematological,
lipid profile and urinalysis parameters were assessed. Pa-
tient demographics, vital signs and date of drug adminis-
tration were also recorded.
Data analysis
In order to pool data from different dosing regimens
used in the three studies, the intravenous (i.v.) doses
were converted to their subcutaneous (s.c.) equivalents
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istration. Subsequently, doses were grouped according to
cumulative and peak exposures and five different treat-
ment groups were defined: placebo, low dose (0.03 mg/kg
i.v. once), intermediate doses (0.1 and 0.3 mg/kg i.v. once,
5 and 15 mg s.c. monthly), medium doses (1.5 mg/kg i.v.
once, 50 mg s.c. monthly and 150 mg s.c. once) and high
doses (10 mg/kg i.v. once and 150 mg s.c. monthly).
Patient demographics, baseline characteristics, durations
of exposure and follow-up were summarised. Owing to
the long half-life of canakinumab (≈26 days), duration of
exposure was defined as the time from first dose to last
dose plus 3 months. The duration of follow-up was calcu-
lated as the time from first dose to the last follow-up visit
plus 1 day.
AEs of special interest related to IL-1β inhibition and
T2DM disease such as infections, malignancy risk, neu-
tropenia, thrombocytopenia, hepatic disorders along
with hypoglycaemia and major adverse cardiovascular
events were analysed. AE coding for all three studies was
updated to version 15.0 of the Medical Dictionary for
Drug Regulatory Activities (MedDRA). AEs were coded
to specific preferred terms (PTs), e.g., ‘Nasopharyngitis’,
which may fall into one or more system organ classes
(SOCs), e.g., ‘Infections and infestations’, of which one is
considered the primary SOC and used for grouping PTs
for reporting. To define the occurrence of AEs of special
interest, current standardised MedDRA queries (SMQ)
were used whenever they existed and were applied to
the data, e.g., ‘Malignancies’ were defined by the narrow
SMQ ‘Malignancies’. The criteria for identifying AEs of
interest are provided in the online appendix (Additional
file 1: Table S1). Laboratory abnormalities were classified
by Common Toxicity Criteria (CTC) grades (grade 1–4).
To provide summary statistics for incidence of AEs that
could be compared across studies of different lengths, the
incidence rate (IR) per subject-month of follow-up was re-
ported. The IR for AEs was defined as the total number of
subjects with any AE divided by the total subject-months
of follow-up until the first AE was reported or the end of
follow-up. The IR for laboratory abnormalities was defined
as subjects with an abnormality per number of post-
baseline visits until the first abnormality occurred. The
IRs for AEs and abnormal laboratory values are referred to
as percentage (%) per month and % per visit, respectively,
throughout the article.
Occurrence of binary outcomes such as AEs and la-
boratory abnormalities was meta-analysed across trials
using Firth penalised likelihood logistic regression, with
log length of follow-up as an offset variable and treat-
ment and study as factors [28]. Continuous laboratory
and vital signs data were meta-analysed using a repeated
measures mixed effects model, with study, treatment,
visit and visit by treatment interaction as factors, andbaseline values as a covariate. Lipid profile parameters
such as total cholesterol (TC), low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) choles-
terol and triglycerides (TG) were analysed on a log scale
using the same approach, and the ratio of geometric
means versus the placebo group was reported. P values
and confidence intervals (CI) were interpreted in a purely
descriptive manner due to lack of pre-specified hypoth-
eses. Thus, any labelling of P values ≤0.05 as statistically
significant has to be considered as purely hypothesis
generating. All AE summaries were also analysed by age
(<65, ≥65) and gender subgroups.
Ethics and good clinical practice
Each of these studies (ClinicalTrials.gov Identifiers NCT
00900146 [24,25], NCT01068860 [26] and NCT00900146/
EUDRACT No. 2007-003729-26 [27]) was conducted as
per the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuti-
cals for Human Use (ICH) good clinical practice guide-
lines and in accordance with the ethical principles of the
Declaration of Helsinki. All study participants provided
written informed consent. All protocols were approved
by the independent ethics committee/institutional re-
view board at each study site or country.
Results
Exposure
The data on durations of exposure and follow-up across
the three pooled clinical studies are provided in Table 1.
The average exposure across all the groups was ≈ 6 months.
In all treatment groups except the low-dose group, 25% of
patients achieved an exposure of 7 to 9 months, with the
maximum exposure being 16 to 17 months. Exposure was
shorter in the low-dose and medium-dose groups due to
the shorter planned duration of the studies involving these
doses.
Demography
The demographic and baseline characteristics by pooled
doses are presented in Table 1. The demographic and
baseline characteristics of patients were generally compar-
able across the treatment groups within each study and
are summarised in online appendix (Additional file 2:
Table S2). The overall mean age of patients was approxi-
mately 55 years with 19.4% of patients aged ≥65 years.
Proportion of men and women was almost equal in most
treatment groups, with a slightly higher percentage of
men in the high-dose group and the placebo group. Pa-
tients were predominantly of Caucasian race across
groups. The overall mean HbA1c value of the study
population was 7.4% with slightly lower values in the
medium-dose canakinumab group (7.1%), which in-
cluded IGT patients unlike the other canakinumab
Table 1 Patient exposure and demographic and baseline characteristics by pooled dose
Canakinumab pooled dose
Low dose Intermediate dose Medium dose High dose Placebo Total
N = 20 N = 247 N = 268 N = 137 N = 354 N = 1026
Duration of exposure (months) 3.00 ± 0.0 7.29 ± 3.057 4.93 ± 2.985 6.79 ± 3.119 5.82 ± 3.250 6.02 ± 3.235
≥3, n (%) 20 (100) 247 (100) 268 (100) 137 (100) 354 (100) 1026 (100)
≥4, n (%) 0 185 (74.9) 89 (33.2) 91 (66.4) 172 (48.6) 537 (52.3)
≥6, n (%) 0 179 (72.5) 87 (32.5) 90 (65.7) 166 (46.9) 522 (50.9)
≥8, n (%) 0 116 (47.0) 54 (20.1) 56 (40.9) 110 (31.1) 336 (32.7)
≥10, n (%) 0 37 (15.0) 19 (7.1) 15 (10.9) 35 (9.9) 106 (10.3)
Subject months of exposure 60.00 1800.61 1320.22 929.68 2067.64 6178.14
Duration of follow-up (months) 5.08 ± 1.426 6.34 ± 2.243 3.40 ± 3.056 6.43 ± 1.691 4.93 ± 2.898 5.07 ± 2.885
<1, n (%) 1 (5.0) 2 (0.8) 111 (41.4) 0 73 (20.6) 187 (18.2)
≥1, n (%) 19 (95.0) 245 (99.2) 157 (58.6) 137 (100) 281 (79.4) 839 (81.8)
≥2, n (%) 18 (90.0) 231 (93.5) 115 (42.9) 137 (100) 252 (71.2) 753 (73.4)
≥3, n (%) 18 (90.0) 228 (92.3) 114 (42.5) 136 (99.3) 251 (70.9) 747 (72.8)
≥4, n (%) 18 (90.0) 227 (91.9) 109 (40.7) 135 (98.5) 247 (69.8) 736 (71.7)
≥6, n (%) 0 123 (49.8) 59 (22.0) 62 (45.3) 115 (32.5) 359 (35.0)
≥8, n (%) 0 40 (16.2) 22 (8.2) 20 (14.6) 40 (11.3) 122 (11.9)
≥10, n (%) 0 12 (4.9) 7 (2.6) 5 (3.6) 15 (4.2) 39 (3.8)
Subject months of follow-up 101.58 1565.43 910.69 881.38 1744.57 5203.65
Demographic variable
Age (years) 53.9 ± 9.07 54.4 ± 9.53 55.7 ± 10.05 54.9 ± 10.14 55.5 ± 9.65 55.2 ± 9.78
<65, n (%) 17 (85.0) 206 (83.4) 210 (78.4) 109 (79.6) 285 (80.5) 827 (80.6)
≥65, n (%) 3 (15.0) 41 (16.6) 58 (21.6) 28 (20.4) 69 (19.5) 199 (19.4)
Sex, n (%)
Male 10 (50.0) 127 (51.4) 138 (51.5) 81 (59.1) 203 (57.3) 559 (54.5)
Female 10 (50.0) 120 (48.6) 130 (48.5) 56 (40.9) 151 (42.7) 467 (45.5)
Race, n (%)
Caucasian 19 (95.0) 134 (54.3) 168 (62.7) 81 (59.1) 218 (61.6) 620 (60.4)
Black 1 (5.0) 12 (4.9) 8 (3.0) 5 (3.6) 14 (4.0) 40 (3.9)
Asian 0 81 (32.8) 77 (28.7) 41 (29.9) 97 (27.4) 296 (28.8)
Others 0 20 (8.1) 15 (5.7) 10 (7.3) 25 (7.0) 70 (6.9)
BMI (kg/m2), n (%)
<30 9 (45.0) 131 (53.0) 115 (42.9) 72 (52.6) 183 (51.7) 510 (49.7)
≥30 11 (55.0) 116 (47.0) 153 (57.1) 65 (47.4) 171 (48.3) 516 (50.3)
HbA1c (%) 7.6 ± 0.79 7.5 ± 0.80 7.1 ± 0.74 7.6 ± 0.76 7.4 ± 0.85 7.4 ± 0.81
FPG (mmol/L) 8.8 ± 1.84 7.9 ± 1.87 7.7 ± 1.86 8.1 ± 1.56 8.0 ± 1.87 7.9 ± 1.83
Duration of type 2 diabetes (years) 5.0 ± 3.62 4.6 ± 4.64 7.0 ± 6.89 4.8 ± 4.70 5.6 ± 5.45 5.5 ± 5.59
Subjects with IGT, n 0 0 28 0 26 54
Diabetes complications, n (%)
Retinopathy NA 3 (1.6) 10 (4.6) 1 (1.1) 8 (3.3) 22 (3.0)
Neuropathy NA 25 (13.3) 27 (12.4) 11 (12.0) 19 (7.8) 82 (11.1)
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Table 1 Patient exposure and demographic and baseline characteristics by pooled dose (Continued)
Nephropathy NA 2 (1.1) 8 (3.7) 4 (4.3) 7 (2.9) 21 (2.8)
Use of statins, n (%) 2 (10.0) 64 (25.9) 104 (38.8) 32 (23.4) 87 (24.6) 289 (28.2)
Data are expressed as mean ± standard deviation (SD), unless otherwise stated.
BMI body mass index; FPG fasting plasma glucose; HbA1c, glycosylated haemoglobin A1c; IGT, impaired glucose tolerance.
Information on the use of statins and diabetes complications was not collected in one of the study (NA).
Low dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c. monthly
and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
Duration of exposure (months) = (date of last dose–date of first dose + 91.2)/30.4.
Duration of follow-up (months) = (date of last follow-up visit–first dose date + 1)/30.4.
Subject months of exposure = sum of the duration of exposure (in months) over all subjects.
Subject months of follow-up = sum of the duration of follow-up (in months) over all subjects.
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index (BMI) <30 kg/m2 and ≥30 kg/m2 was almost simi-
lar in most treatment groups. Mean duration of T2DM
was approximately 5 years, except for the medium-dose
group with 7 years. This is because one study of the
medium dose versus placebo allowed the inclusion of
patients receiving multiple oral drugs with or without
insulin, which typically reflects advanced disease stages.
The proportion of patients using statins was 20% to 40%
in all groups, except the low-dose group at 10%. Diabetic
neuropathy was a more common complication among pa-
tients across groups than retinopathy or nephropathy.
Safety and tolerability
Overall, incidences of any AEs, any SAEs and discontinua-
tions due to any AEs are summarised in Table 2. A trend
towards more patients having at least one AE across cana-
kinumab doses relative to placebo (P = 0.0152) was seen.
SAEs were few and the IR was lower in most of the cana-
kinumab groups compared with the placebo group, except
in the high-dose group (0.94% versus 0.58% per month for
placebo). There were no SAEs reported in patients receiv-
ing low-dose canakinumab. Treatment discontinuation due
to AEs was reported in five patients across groups. There
were no deaths reported in any of the studies.
Adverse events
When the reported AEs were analysed by primary SOC
(Table 2), there were no major imbalances in IRs be-
tween the canakinumab and placebo groups. A slightly
higher IR of AEs was reported in canakinumab-treated
patients compared with placebo under the SOCs of in-
fections and infestations, gastrointestinal, renal and urin-
ary disorders and investigations. Conversely, a slightly
lower incidence of AEs was reported in canakinumab-
treated patients compared with placebo under the SOCs
of cardiac disorders (except low-dose group) and skin
and subcutaneous tissue disorders (except medium-dose
group). Table 3 provides a summary of the most com-
monly reported AEs by preferred terms (occurring in at
least five patients and ≥2% in any of the group). The
most common AE preferred terms reported across treat-
ment groups were nasopharyngitis, bronchitis, urinarytract infection, upper respiratory tract infection and head-
ache. The IR of urinary tract infection AEs was lower
across canakinumab doses compared with the placebo
group with the exception of the low-dose canakinumab
group. The IRs of upper respiratory tract infection ap-
peared slightly higher for all canakinumab doses—except
for the low dose—relative to placebo. There was no imbal-
ance between canakinumab doses and the placebo group
for nasopharyngitis, arthralgia, pain in extremity and
headaches.
Serious adverse events
There were no appreciable trends in SAEs observed, and
the majority of SAEs were scattered across different SOCs
(Table 4). According to the primary SOC, the highest inci-
dence of SAEs across different groups was ‘infections and
infestations’ with a higher IR for the high-dose canakinu-
mab group (three patients, IR = 0.34% per month) com-
pared with placebo (two patients, IR = 0.12% per month).
Canakinumab was associated with a lower IR of cardiac
SAEs than placebo (high dose: one patient, IR = 0.11% per
month; placebo: five patients, IR = 0.29% per month).
Adverse events of special interest
AEs of special interest including those potentially related
to IL-1β inhibition and T2DM disease are presented in
Table 5. Although the rate of infections was numerically
higher in all canakinumab groups (4.41%, 4.05%, 5.13%
and 4.02% per month in low, intermediate, medium and
high doses, respectively) than placebo (3.17% per month),
the difference was not statistically significant—neither for
each individual dose nor when tested for a monotonic
trend across doses versus placebo (P = 0.1255). Infections
were primarily recorded due to unspecified pathogens
affecting the upper and lower respiratory tract, other in-
fections were recorded as viral or bacterial infections.
Hypersensitivity/allergy IRs was lower in all canakinu-
mab doses compared with placebo with the exception of
the medium dose (1.02% versus 0.84% per month). The
IR of thrombocytopenia AEs were higher across all
canakinumab groups (1.04%, 0.46%, 0.56% and 0.46% per
month in low-, intermediate-, medium- and high-dose
groups, respectively) compared with placebo (0.23% per
Table 2 Summary of adverse events reported in the pooled data
Canakinumab pooled dose Placebo
Low dose Intermediate dose Medium dose High dose
N = 20 N = 247 N = 268 N = 137 N = 354
Any AEs
n (%) 10 (50.0) 107 (43.3) 103 (38.4) 67 (48.9) 134 (37.9)
IR (%) 16.31 10.28 16.45 12.14 11.45
Discontinuations due to any AEs
n (%) 1 (5.0) 1 (0.4) 0 2 (1.5) 1 (0.3)
IR (%) 0.99 0.06 0.23 0.06
Any serious AEs
n (%) 0 4 (1.6) 5 (1.9) 8 (5.8) 10 (2.8)
IR (%) 0 0.26 0.55 0.94 0.58
Deaths
n (%) 0 0 0 0 0
AEs by primary SOCs (occurring in ≥5% of patients in any group)
Infections and infestations
n (%) 4 (20.0) 54 (21.9) 40 (14.9) 30 (21.9) 49 (13.8)
IR (%) 4.41 4.05 5.13 4.02 3.17
Musculoskeletal and connective tissue disorders
n (%) 1 (5.0) 22 (8.9) 14 (5.2) 11 (8.0) 27 (7.6)
IR (%) 1.03 1.48 1.62 1.33 1.65
Gastrointestinal disorders
n (%) 1 (5.0) 12 (4.9) 17 (6.3) 12 (8.8) 21 (5.9)
IR (%) 1.04 0.80 1.98 1.44 1.26
Cardiac disorders
n (%) 1 (5.0) 8 (3.2) 4 (1.5) 3 (2.2) 12 (3.4)
IR (%) 1.04 0.53 0.44 0.35 0.71
Eye disorders
n (%) 3 (15.0) 5 (2.0) 6 (2.2) 2 (1.5) 7 (2.0)
IR (%) 3.40 0.33 0.67 0.23 0.41
Renal and urinary disorders
n (%) 1 (5.0) 5 (2.0) 5 (1.9) 5 (3.6) 3 (0.8)
IR (%) 1.04 0.32 0.55 0.58 0.17
Investigations
n (%) 0 12 (4.9) 13 (4.9) 16 (11.7) 15 (4.2)
IR (%) 0.79 1.50 1.96 0.89
Skin and subcutaneous tissue disorders
n (%) 0 10 (4.0) 11 (4.1) 7 (5.1) 16 (4.5)
IR (%) 0.65 1.25 0.83 0.95
n (%) are expressed as number (%) of patients; incidence rate (IR) is expressed as % per month.
Low dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c. monthly
and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
SOC system organ class.
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sion AEs between the canakinumab and placebo groups.
Major adverse cardiovascular events occurred in pa-
tients of all groups, except the low-dose group; however,incidences in the intermediate-, medium- and high-dose
groups were lower versus the placebo group (0.19%,
0.44% and 0.23% versus 0.53% per month, respectively).
This observed difference in favour of canakinumab was
Table 3 Incidence of most common adverse events (occurring in at least five patients and in ≥2% in any group) by
preferred term
Preferred term Canakinumab pooled dose Placebo
Low dose Intermediate dose Medium dose High dose
N = 20 N = 247 N = 268 N = 137 N = 354
Nasopharyngitis
n (%) 0 15 (6.1) 10 (3.7) 11 (8.0) 21 (5.9)
IR (%) 1.00 1.15 1.31 1.26
Bronchitis
n (%) 0 9 (3.6) 3 (1.1) 1 (0.7) 2 (0.6)
IR (%) 0.59 0.33 0.11 0.11
Urinary tract infection
n (%) 3 (15.0) 7 (2.8) 5 (1.9) 5 (3.6) 11 (3.1)
IR (%) 3.15 0.46 0.56 0.58 0.64
Upper respiratory tract infection
n (%) 0 6 (2.4) 3 (1.1) 4 (2.9) 4 (1.1)
IR (%) 0.39 0.33 0.47 0.23
Arthralgia
n (%) 0 5 (2.0) 3 (1.1) 3 (2.2) 7 (2.0)
IR (%) 0.32 0.33 0.35 0.41
Pain in extremity
n (%) 0 5 (2.0) 4 (1.5) 3 (2.2) 5 (1.4)
IR (%) 0.32 0.44 0.35 0.29
Headache
n (%) 4 (1.6) 2 (0.7) 5 (3.6) 8 (2.3)
IR (%) 0.26 0.22 0.58 0.47
Cough
n (%) 2 (0.8) 3 (1.1) 2 (1.5) 7 (2.0)
IR (%) 0.13 0.33 0.23 0.41
Oropharyngeal pain
n (%) 5 (2.0) 0 2 (1.5) 0
IR (%) 0.32 0.23
n (%) are expressed as number (%) of patients; incidence rate (IR) is expressed as % per month.
Low dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c. monthly
and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
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dose nor when tested for a monotonic trend across
doses versus placebo (P = 0.9371).
The IR of hepatic disorders AEs was higher in the
high-dose canakinumab (0.70% per month) than in the
other canakinumab groups (0%, 0.06% and 0.22% per
month for low, intermediate and medium groups, re-
spectively) or placebo (0.12% per month), with an odds
ratio versus placebo of 6.217 (95% CI: 1.504–25.697;
P = 0.0116). Six patients in the high-dose group reported
events, mainly hepatic steatosis and abnormality in hepatic
enzymes levels such as aspartate aminotransferase (AST),aspartate alanine transferase (ALT) elevations, but none of
abnormalities based on the central laboratory exceeded >3
times upper limit of normal (ULN) range.
Injection-site reactions and hypoglycaemic events were
only reported in patients who received medium dose of
canakinumab or placebo with slightly higher rates in the
medium dose than placebo (0.22% versus 0.12% per
month and 0.22% versus 0.06% per month, respectively).
AEs of lymphoid organ toxicity, malignancies and neu-
tropenia were only observed in one patient for each
event and changes in renal function were observed in
two patients receiving canakinumab.
Table 4 Incidence of serious adverse events by primary SOC
Canakinumab pooled dose Placebo
Low dose Intermediate dose Medium dose High dose
N = 20 N = 247 N = 268 N = 137 N = 354
Infections and infestations
n (%) 0 1 (0.4) 1 (0.4) 3 (2.2) 2 (0.6)
IR (%) 0.06 0.11 0.34 0.12
Renal and urinary disorders
n (%) 0 1 (0.4) 2 (0.7) 1 (0.7) 1 (0.3)
IR (%) 0.06 0.22 0.11 0.06
Gastrointestinal disorders
n (%) 0 0 1 (0.4) 1 (0.7) 1 (0.3)
IR (%) 0.11 0.11 0.06
Cardiac disorders
n (%) 0 0 0 1 (0.7) 5 (1.4)
IR (%) 0.11 0.29
Hepatobiliary disorders
n (%) 0 0 1 (0.4) 0 1 (0.3)
IR (%) 0.11 0.06
General disorders and administration site conditions
n (%) 0 0 0 0 1 (0.3)
IR (%) 0.06
Musculoskeletal and connective tissue disorders
n (%) 0 1 (0.4) 0 0 1 (0.3)
IR (%) 0.06 0.06
Metabolism and nutrition disorders
n (%) 0 0 0 2 (1.5) 0
IR (%) 0.23
Investigations
n (%) 0 0 0 1 (0.7) 0
IR (%) 0.11
Neoplasms—benign, malignant and unspecified (including cysts and polyps)
n (%) 0 0 0 1 (0.7) 0
IR (%) 0.11
Injury, poisoning and procedural complications
n (%) 0 0 1 (0.4) 0 0
IR (%) 0.11
Nervous system disorders
n (%) 0 1 (0.4) 0 0 0
IR (%) 0.06
Reproductive system and breast disorders
n (%) 0 1 (0.4) 0 0 0
IR (%) 0.06
n (%) are expressed as number (%) of patients; incidence rate (IR) is expressed as % per month.
Low dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c. monthly
and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
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Table 5 Adverse events of special interest including class effect (IL-1β inhibition) and disease effect (T2DM)
Canakinumab pooled dose Placebo
Low dose Intermediate dose Medium dose High dose
N = 20 N = 247 N = 268 N = 137 N = 354
Infections
n (%) 4 (20.0) 54 (21.9) 40 (14.9) 30 (21.9) 49 (13.8)
IR (%) 4.41 4.05 5.13 4.02 3.17
Hypersensitivity/allergy
n (%) 0 9 (3.6) 9 (3.4) 6 (4.4) 14 (4.0)
IR (%) 0 0.59 1.02 0.70 0.84
Thrombocytopenia
n (%) 1 (5.0) 7 (2.8) 5 (1.9) 4 (2.9) 4 (1.1)
IR (%) 1.04 0.46 0.56 0.46 0.23
Hypertension
n (%) 0 5 (2.0) 3 (1.1) 3 (2.2) 6 (1.7)
IR (%) 0 0.32 0.33 0.35 0.35
Major adverse cardiovascular events (MACE)
n (%) 0 3 (1.2) 4 (1.5) 2 (1.5) 9 (2.5)
IR (%) 0 0.19 0.44 0.23 0.53
Hepatic disorders
n (%) 0 1 (0.4) 2 (0.7) 6 (4.4) 2 (0.6)
IR (%) 0 0.06 0.22 0.70 0.12
Vertigo
n (%) 0 1 (0.4) 5 (1.9) 4 (2.9) 6 (1.7)
IR (%) 0 0.06 0.56 0.46 0.3
Injection-site reactions
n (%) 0 0 2 (0.7) 0 2 (0.6)
IR (%) 0 0 0.22 0 0.12
Hypoglycaemia
n (%) 0 0 2 (0.7) 0 1 (0.3)
IR (%) 0 0 0.22 0 0.06
Changes in renal function
n (%) 0 1 (0.4) 1 (0.4) 0 0
IR (%) 0 0.06 0.11 0 0
Lymphoid organ toxicity
n (%) 0 0 1 (0.4) 0 0
IR (%) 0 0 0.11 0 0
Malignancies
n (%) 0 0 0 1 (0.7) 0
IR (%) 0 0 0 0.11 0
Neutropenia
n (%) 0 1 (0.4) 0 0 0
IR (%) 0 0.06 0 0 0
n (%) are expressed as number (%) of patients; incidence rate (IR) is expressed as % per month.
Low dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c. monthly
and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
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Specified abnormalities in haematology and biochemistry
parameters are summarised in Table 6 and treatment
group averages over time are presented in Figure 1. De-
crease in total WBC counts was observed on canakinu-
mab (Figure 1A) with no clear dose-related pattern.
Patients receiving intermediate, medium and high doses
of canakinumab had a higher IR of abnormally low total
WBC (2.14%, 3.22% and 1.86% per visit, respectively)
than the placebo group (1.25% per visit). Most of these
abnormalities were grade 1. Only two patients (one each
in intermediate and placebo groups) had a grade 3
abnormality. There was no clear association between
patients with abnormal WBC counts and those who had
infections. There was also a decrease in absolute neu-
trophil counts (Figure 1B) with a higher IR of abnormal
neutrophil counts in patients receiving intermediate
(2.68% per visit), medium (4.95% per visit) and high
doses (4.61% per visit) than in those receiving low-dose
canakinumab (0.89% per visit) or placebo (1.22% per
visit). The difference was statistically significant for each
individual dose or when tested for a monotonic trend
across doses versus placebo (P = 0.0001). No CTC grade
3 or 4 abnormality was observed. There was no clear as-
sociation between patients with abnormal neutrophil
counts and those who had infections. There was also a
decrease in mean platelet counts (Figure 1C) with no
clear dose-related pattern. Patients receiving intermediate
and medium doses showed similar IRs of platelet count
abnormality compared with placebo (1.23%, 1.57% versus
1.00% per visit, respectively), whereas lower IRs were re-
ported for the low and high canakinumab doses relative to
placebo (0.92%, 0.73% versus 1.00% per visit, respectively).
Of note, this decrease in platelet counts in canakinumab-
treated patients versus placebo was no longer apparent
after 5 months. Most of the abnormalities in platelet count
reported were grade 1 or 2 with a comparable IR as in the
placebo group. No patients with abnormal platelet counts
had a bleeding disorder. No difference in the IR for ab-
normal absolute lymphocyte counts was seen between
the canakinumab and placebo groups. Data show a trend
towards higher haemoglobin levels in canakinumab
groups compared with placebo, which persisted for at
least 5 months of treatment (Figure 1D).
Increases in mean SGPT (ALT) levels were noted, which
did not worsen over time (Figure 1E). These increases
were less discernible in SGOT (AST) levels (Figure 1F).
The IRs of elevations in hepatic enzymes CTC grade 1
were 0%, 0.21%, 0.69%, 0.88% and 0.17% per visit for
SGPT and 0%, 0.11%, 0%, 0.35% and 0% per visit for
SGOT in the low-, intermediate-, medium-, high-doses
and placebo groups, respectively. There was also an in-
crease in mean levels of total bilirubin, which were, how-
ever, no longer discernible after 7 months of treatment(Figure 1G). There was no difference in incidence of el-
evated bilirubin levels reported in medium- and high-
dose groups versus placebo. The reported abnormalities
were of grade 1 or 2 except one patient in the placebo
group who had grade 3 abnormality. The monotonic
trend across doses was statistically significant versus pla-
cebo (P = 0.0158) for SGPT abnormalities, whereas this
was not the case for SGOT and bilirubin levels. There
were no potential Hy’s Law cases (ALT or AST ≥3xULN
and total bilirubin >2xULN) reported in any of the three
studies.
An increase in average TC (medium dose: 3%, 2%, 8%
and 4%; high dose: 7%, 5%, 8% and 5% for Months 1 to
4, Figure 1H) and TG (high dose: 11%, 15%, 14% and
10% for Months 1 to 4) levels was seen in patients
treated with medium and/or high doses of canakinumab
for at least the initial 4 months compared with placebo.
Average HDL-C was higher in the high dose (5% for
Month 1) and medium dose (7% and 5% for Months 1
and 2) than placebo during the first 2 months of treat-
ment. No clear time pattern was identified for LDL-C.Changes in vital signs
Modest increases from baseline in systolic and diastolic
blood pressures were generally observed in the canaki-
numab groups throughout the duration of the observation
period. However, the majority of these changes in either
systolic or diastolic blood pressure were not significantly
different from those seen in placebo and had no particular
dose-related or temporal trend. There was no clear dose
response or trend seen in changes in the pulse rate in pa-
tients treated with canakinumab. No considerable change
in body weight was observed across groups.Sub group analyses by age and gender
Total AEs, SAEs, haematology and biochemistry parame-
ters were analysed by age (<65 and ≥65 years) and gender
versus placebo and are summarised in online appendix
(Additional file 3: Table S3). Findings in age subgroups
were generally similar to those in the overall population
with no notable differences in the safety profile of canaki-
numab. Women treated with canakinumab reported nu-
merically higher incidences of any AEs than women in the
placebo group. In contrast, incidences of any AEs in men
treated with canakinumab were lower than those treated
with placebo, except in patients receiving intermediate
dose who showed a slight increase in AEs compared with
the placebo group. However, the incidences of any SAEs
in men and women were generally comparable with pla-
cebo and no notable differences to the overall population
were observed with respect to laboratory values and vital
signs.
Table 6 Number of subjects (incidence rates) with specified abnormalities in haematology and biochemistry
parameters during any time of the post-treatment follow-up period
Canakinumab pooled dose Placebo
Low dose Intermediate dose Medium dose High dose
I. Haematology parameters
WBC (total) (109/L), N 20 245 262 136 342
Any grade 1–4 abnormality, n 0 19 18 10 14
IR (%) 0.0 2.14 3.22 1.86 1.25
Dose trend test, P value 0.0884
G1 (<LLN–3.0), n (%) 0 18 (7.3) 15 (5.7) 10 (7.4) 13 (3.8)
IR (%) 0.0 2.03 2.68 1.86 1.16
G2 (<3.0–2.0), n (%) 0 1 (0.4) 4 (1.5) 1 (0.7) 1 (0.3)
IR (%) 0.0 0.11 0.68 0.18 0.09
Absolute neutrophil counts (Seg. + bands) (109/L), N 20 222 258 93 288
Any grade 1–4 abnormality, n 1 21 27 13 10
IR (%) 0.89 2.68 4.95 4.61 1.22
Dose trend test, P value 0.0001
G1 (<LLN–1.5), n (%) 0 17 (7.7) 23 (8.9) 13 (14.0) 7 (2.4)
IR (%) 0.0 2.13 4.17 4.59 0.85
G2 (<1.5–1.0), n (%) 1 (5.0) 6 (2.7) 7 (2.7) 2 (2.2) 2 (0.7)
IR (%) 0.89 0.74 1.26 0.66 0.24
Platelet counts (direct) (109/L), N 20 245 260 136 342
Any grade 1–4 abnormality, n 1 11 9 4 11
IR (%) 0.92 1.23 1.57 0.73 1.00
Dose trend test, P value 0.9488
G1 (<LLN–75), n (%) 1 (5.0) 10 (4.1) 9 (3.5) 4 (2.9) 11 (3.2)
IR (%) 0.92 1.11 1.57 0.73 1.00
G2 (<75–50), n (%) 0 0 0 1 (0.7) 0
IR (%) 0.0 0.0 0.0 0.18 0.0
Absolute lymphocyte counts (109/L), N 20 222 258 93 288
Any grade 1–4 abnormality, n 0 2 3 1 7
IR (%) 0.0 0.25 0.53 0.33 0.85
Dose trend test, P value 0.2241
G1 (<LLN–0.8), n (%) 0 0 1 (0.4) 0 3 (1.0)
IR (%) 0.0 0.0 0.18 0.0 0.36
G2 (<0.8–0.5), n (%) 0 2 (0.9) 2 (0.8) 1 (1.1) 4 (1.4)
IR (%) 0.0 0.25 0.36 0.33 0.48
Haemoglobin (g/L), N 20 245 262 136 342
Any grade 1–4 abnormality, n 8 49 36 31 76
IR (%) 9.20 6.27 6.83 6.68 7.97
Dose trend test, P value 0.1239
G1 (<LLN–100), n (%) 8 (40.0) 49 (20.0) 33 (12.6) 30 (22.1) 73 (21.3)
IR (%) 9.09 6.23 6.24 6.41 7.63
G2 (<100–80), n (%) 1 (5.0) 5 (2.0) 3 (1.1) 2 (1.5) 5 (1.5)
IR (%) 0.90 0.54 0.51 0.36 0.44
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Table 6 Number of subjects (incidence rates) with specified abnormalities in haematology and biochemistry
parameters during any time of the post-treatment follow-up period (Continued)
II. Biochemistry parameters
SGPT (ALT) (U/L), N 20 245 262 136 343
Any grade 1–4 abnormality, n 0 2 4 5 2
IR (%) 0.0 0.21 0.69 0.88 0.17
Dose trend test, P value 0.0158
G1 (>3–5×ULN), n (%) 0 2 (0.8) 4 (1.5) 5 (3.7) 2 (0.6)
IR (%) 0.0 0.21 0.69 0.88 0.17
SGOT (AST) (U/L), N 20 245 256 136 342
Any grade 1–4 abnormality, n 0 1 0 2 0
IR (%) 0.0 0.11 0.0 0.35 0.0
Dose trend test, P value 0.0777
G1 (>3–5×ULN), n (%) 0 1 (0.4) 0 2 (1.5) 0
IR (%) 0.0 0.11 0.0 0.35 0.0
Bilirubin (total) (μmol/L), N 20 245 265 136 344
Any grade 1–4 abnormality, n 0 0 3 4 6
IR (%) 0.0 0.0 0.52 0.70 0.52
Dose trend test, P value 0.6430
G1 (>1.5–2×ULN), n (%) 0 0 2 (0.8) 3 (2.2) 5 (1.5)
IR (%) 0.0 0.0 0.34 0.52 0.44
G2 (>2–3×ULN), n (%) 0 0 2 (0.8) 2 (1.5) 0
IR (%) 0.0 0.0 0.34 0.35 0.0
Alkaline phosphatase, serum (U/L), N 20 245 263 136 344
Any grade 1–4 abnormality, n 0 0 0 0 1
IR (%) 0.0 0.0 0.0 0.0 0.09
Dose trend test, P value 0.2357
G1 (>2–3×ULN), n (%) 0 0 0 0 1 (0.3)
IR (%) 0.0 0.0 0.0 0.0 0.09
G2 (>3–5×ULN), n (%) 0 0 0 0 1 (0.3)
IR (%) 0.0 0.0 0.0 0.0 0.09
Creatinine (umol/L), N 20 245 265 136 344
Any grade 1–4 abnormality, n 1 10 11 6 10
IR (%) 0.91 1.06 1.89 1.06 0.88
Dose trend test, P value 0.3490
G1 (>ULN–1.5×ULN), n (%) 1 (5.0) 10 (4.1) 11 (4.2) 6 (4.4) 10 (2.9)
IR (%) 0.91 1.06 1.88 1.06 0.88
G2 (>1.5–3×ULN), n (%) 0 1 (0.4) 1 (0.4) 0 0
IR (%) 0.0 0.11 0.17 0.0 0.0
Abnormalities are presented as number (n) and/or % of patients. Incidence rate (IR) is expressed as % per visit. Subjects are counted only once if specified
abnormality occurred multiple times during the treatment or post-treatment follow-up period. Subjects can be counted more than once in multiple categories
and grades. The Jonckheere-Terpstra test was used to test for a monotonic trend across doses in the proportion of post-baseline visits with any laboratory
abnormality among the total number of post-baseline visits.
CTC, common terminology criteria; G, grade; WBC, white blood cell; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.
Low dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c. monthly
and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
Total WBC count: Normal range = 4.5–11.0 × 109/L; Absolute neutrophil counts: Normal range = 1.5–8.0 × 109/L; Haemoglobin: Normal range = 13.5–17.5% (males)
and 12.0–16.0% (females); Platelet count (direct): Normal range = 150–450 × 109/L; Absolute lymphocyte count: Normal range = 1.0–4.0 × 109/L; SGOT (AST): Normal
range = 3–44 U/L; SGPT (ALT): Normal range = 0–40 U/L; Bilirubin (total): Normal range = 5–17.0 μmol/L; Alkaline phosphatase, serum: Normal range = 30–125 U/L;
Creatinine: Normal range = 45–90 μmol/L (females) and 60–110 μmol/L (males).









































































































































































































Figure 1 (See legend on next page.)
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Figure 1 Model-adjusted change from baseline in haematological and biochemistry parameters, by time point. A). White blood cell
counts (total) (109/L). B). Absolute neutrophil counts (109/L). C). Platelet count (direct) (109/L). D). Haemoglobin (g/L). E). Serum glutamic pyruvic
transaminase/ALT (U/L). F). Serum glutamic oxaloacetic transaminase/AST (U/L). G). Bilirubin (total) (μmol/L). H). Cholesterol (total) (mmol/L). Low
dose: 0.03 mg/kg i.v. once; intermediate dose: 0.1 and 0.3 mg/kg i.v. once, 5 and 15 mg s.c. monthly; medium dose: 1.5 mg/kg i.v. once, 50 mg s.c.
monthly and 150 mg s.c. once; high dose: 10 mg/kg i.v. once and 150 mg s.c. monthly.
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Inflammation plays a major role in endothelial dysfunc-
tion and the development of atherothrombosis. There
are several novel targets available to inhibit these inflam-
matory changes at the vascular level such as tumor ne-
crosis factor-α (TNF-α) blocker (etanercept, rilonacept,
infliximab, adalimumab), IL-6 receptor antagonist (toci-
lizumab), IL-1a receptor antagonist (anakinra) and IL-1β
(canakinumab) [29]; and steroidogenic acute regulatory
protein, so far studied only in rats [30]. Targeting of the
IL-1 pathways in disease treatment raises possible safety
concerns due to inhibition of innate immunity [31]. This
large pooled analysis included more than 1000 patients
with type 2 diabetes mellitus (mean duration: ~5 years)
treated for up to 1.4 years either with canakinumab, an
IL-1β blocker or placebo. It was of particular interest to
assess the combined safety data from individual studies
to help identify any significant findings, including dose
response, from the pooled analysis.
Overall, there were no clinically meaningful differences
in AEs and SAEs between canakinumab-treated patients
and placebo, with no clear dose-dependent trends in
AEs. The observed safety findings and overall tolerability
in patients with T2DM are consistent with those in previ-
ously reported studies in patients with cryopyrin-associated
periodic syndrome, gouty arthritis and systemic juvenile
idiopathic arthritis [21-23].
The mode of action of canakinumab is to inhibit in-
nate immunity while binding to IL-1β [31], therefore, an
increased rate of infections was expected in each canaki-
numab dose group versus placebo. The most commonly
reported AEs in this pooled analyses were nasopharyngi-
tis, urinary tract infections and upper respiratory tract
infections. The observed increase in rate of infections
with canakinumab was, however, not statistically signifi-
cant. This numerical imbalance is, nevertheless, most
likely a true signal due to its biological plausibility. Im-
portantly, the clinical experience with canakinumab dif-
fers from that of TNF-α blockers which are associated
with an increased risk of tuberculosis reactivation [32].
Studies reveal that tuberculosis risk varies with the use
of different anti-TNF-α agents (etanercept, 35 cases per
100,000 patients; infliximab, 144 per 100,000 patients;
and adalimumab, 240 per 100,000 patients) [33]. Wallis
et al. [34] showed that the probability of tuberculosis de-
veloping with infliximab treatment is threefold higher than
with etanercept. Similar to anakinra [35], canakinumabhas not been associated with the risk of tuberculosis
reactivation, indicating that blocking the IL-1 pathway
is safer in comparison with blocking TNF-α.
Of the seven patients who experienced serious infec-
tions, five were observed on canakinumab and two on
placebo. Four of the five canakinumab-treated subjects
had a complete recovery and in one case outcome was
not reported after the patient was taken off the study
drug. No relationship between the events and study
drug was reported by the investigators for the patients
who reported an outcome. Moreover, there were no sig-
nificant changes in the WBC counts in these seven pa-
tients, with the only value falling below the normal
range at month 4 (3.12×109/L; baseline 7.13×109/L) in a
patient taking placebo which returned to normal range
at month 6 (5.38×109/L). Although none of the patients
had WBC values above the upper limit of normal range
throughout the study, two patients reported leucocyt-
osis associated with their acute infection. There were no
significant changes in hsCRP levels in these patients.
AEs of injection-site reactions, malignancies, neutro-
penia and changes in renal function were infrequent
with no apparent dose-dependent trend. Although IL-1β
inhibition increases expression of the pancreatic β-cells
in T2DM patients [13], the present study reported only
two hypoglycaemic events with medium-dose canaki-
numab (versus one on placebo), which were mild-to-
moderate in severity and none was suspected by the
investigators to be related to the study drug. None of
the patients had reported any asymptomatic low blood
glucose (<40 mg/dL) event or discontinued their study
treatment permanently because of any hypoglycaemic
event, thereby suggesting that canakinumab did not
result in increased risk of hypoglycaemic events in T2DM
patients. Although a lower rate of major adverse cardio-
vascular events was observed in the canakinumab groups
compared with the placebo group, the low number of
events prevents drawing conclusions on the significance of
this observation.
The decreases in platelet counts and absolute neutrophil
counts and the resulting decreased total WBC counts are
well-known effects of canakinumab treatment [21-23] due
to the role of IL-1β in bone marrow maturation and re-
lease of these blood cells [31]. Most laboratory abnormal-
ities observed in this pooled analysis were of CTC grades
1 or 2, and there was no association of any such events
either with infections or bleeding/bruising.
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was low and was driven by a small number of patients
with a known high prevalence of hepatic steatosis. There
were no cases consistent with Hy’s law. Vital signs of the
patients treated with canakinumab showed no clinically
meaningful difference versus placebo and had no par-
ticular dose-related trend. Treatment with canakinumab
did not seem to have a clinically meaningful effect on
lipid profiles in patients with T2DM or IGT. The in-
crease in TC levels appeared to be due to an increase in
HDL-C, because no clear pattern was observed for LDL-C.
The clinical significance of the increase in TG levels could
not be determined in the absence of increase in LDL-C
levels.
Treatment-emergent AEs leading to permanent dis-
continuation of study treatment were rare and evenly
distributed in all treatment groups, demonstrating the
good tolerability and safety of canakinumab. No deaths
were reported in any of the three studies. The subgroup
analyses by age (<65 and ≥65 years) and gender showed
no remarkable observations related to the safety findings
of canakinumab when compared with overall population.
Safety findings from this pooled data set were consistent
with the previously reported studies in patients with
cryopyrin-associated periodic syndrome, gouty arthritis
and systemic juvenile idiopathic arthritis [21-23] with no
new safety findings. In addition, a recent study in newly
diagnosed type 1 diabetes patients (mostly less than
18 years of age) treated with IL-1Ra (anakinra) and IL-1β
(canakinumab) inhibitors revealed no major safety con-
cerns although they failed to prevent deterioration of
endogenous pancreatic insulin (C-peptide) secretion in
these patients [36]. However, in a preclinical study [37],
the combination of IL-1β blocker with other anti-CD3
monoclonal antibody resulted in significantly greater
clinical remission of diabetes suggesting that this com-
bination might be more suitable in new onset type 1
diabetes or in prevention trials in individuals with pre-
type 1 diabetes.
By pooling three T2DM studies we obtained a pooled
safety database of 1026 patients, which allowed a better
characterisation of the safety profile of canakinumab
than was possible in each individual trial [24-27]. Never-
theless, this sample size was still too small to conclusively
evaluate all potential observed safety issues, which may
have included spurious chance findings. It also does not
allow a proper evaluation of extremely rare events (such
as malignancies, neutropenia or renal function). Another
key limitation of this pooled safety analysis is that the dur-
ation of treatment and follow-up was on average 6 months
and only exceeded 1 year in a small subset of patients.
This precludes any definite conclusions regarding the
long-term safety of canakinumab in patients with T2DM
or IGT. However, CANTOS, an ongoing large outcomesstudy, is evaluating three doses of canakinumab (50,
150 and 300 mg versus placebo) given subcutaneously
on a quarterly basis for up to 5 years in order to assess
the effects on cardiovascular risk reduction in post-MI
patients and will provide long term safety data on
canakinumab [20].
In conclusion, this pooled safety analysis over a treat-
ment period of 1.4 years indicates that canakinumab
across the evaluated doses in T2DM or IGT patients is
safe and well tolerated, adding important information to
the overall safety profile of the drug.
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